Nurix Other Liab vs Capital Surpluse Analysis

NRIX Stock

USD 15.90 0.95 6.35%

Nurix TherapeuticsInc financial indicator trend analysis is infinitely more than just investigating Nurix TherapeuticsInc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nurix TherapeuticsInc is a good investment. Please check the relationship between Nurix TherapeuticsInc Other Liab and its Capital Surpluse accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nurix TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Nurix Stock please use our How to Invest in Nurix TherapeuticsInc guide.

Other Liab vs Capital Surpluse

Other Liab vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nurix TherapeuticsInc Other Liab account and Capital Surpluse. At this time, the significance of the direction appears to have strong relationship.

The correlation between Nurix TherapeuticsInc's Other Liab and Capital Surpluse is 0.77. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Nurix TherapeuticsInc, assuming nothing else is changed. The correlation between historical values of Nurix TherapeuticsInc's Other Liab and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of Nurix TherapeuticsInc are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Other Liab i.e., Nurix TherapeuticsInc's Other Liab and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Other Liab

Capital Surpluse

Most indicators from Nurix TherapeuticsInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nurix TherapeuticsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nurix TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Nurix Stock please use our How to Invest in Nurix TherapeuticsInc guide.At this time, Nurix TherapeuticsInc's Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value is likely to rise to about 475.4 M in 2024, whereas Selling General Administrative is likely to drop slightly above 26.3 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	3.5M	11.1M	12.8M	13.4M
Net Interest Income	3.5M	11.1M	12.8M	13.4M

Interest Income Net Interest Income

Nurix TherapeuticsInc fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.79	0.85	0.99	0.88	0.99	0.75	0.76	-0.57	-0.8	0.94	0.87	0.96	0.83	0.4	0.99	0.98	0.75	0.97	0.47	0.92	0.98	0.81	0.81	0.99	0.67
Other Current Liab	0.79		0.89	0.73	0.61	0.79	0.98	0.78	0.01	-0.98	0.88	0.48	0.67	0.91	-0.08	0.82	0.83	0.89	0.87	0.54	0.96	0.83	1.0	0.87	0.73	0.95
Total Current Liabilities	0.85	0.89		0.79	0.59	0.89	0.88	0.95	-0.12	-0.91	0.95	0.53	0.72	0.92	0.06	0.89	0.92	0.85	0.94	0.49	0.9	0.86	0.9	0.92	0.79	0.84
Total Stockholder Equity	0.99	0.73	0.79		0.88	0.98	0.68	0.71	-0.64	-0.73	0.89	0.89	0.97	0.79	0.45	0.97	0.96	0.68	0.94	0.38	0.89	0.98	0.76	0.73	1.0	0.59
Other Liab	0.88	0.61	0.59	0.88		0.85	0.59	0.42	-0.69	-0.62	0.79	0.91	0.88	0.6	0.53	0.86	0.84	0.67	0.8	0.66	0.77	0.83	0.62	0.71	0.88	0.53
Net Tangible Assets	0.99	0.79	0.89	0.98	0.85		0.76	0.8	-0.53	-0.82	0.95	0.84	0.93	0.85	0.39	1.0	0.99	0.77	0.99	0.49	0.92	0.97	0.82	0.84	0.98	0.69
Property Plant And Equipment Net	0.75	0.98	0.88	0.68	0.59	0.76		0.78	0.04	-0.97	0.86	0.47	0.62	0.84	-0.05	0.79	0.8	0.85	0.83	0.61	0.94	0.77	0.97	0.89	0.68	0.99
Current Deferred Revenue	0.76	0.78	0.95	0.71	0.42	0.8	0.78		-0.09	-0.79	0.85	0.47	0.64	0.79	0.08	0.79	0.81	0.65	0.84	0.32	0.79	0.75	0.79	0.81	0.71	0.76
Net Debt	-0.57	0.01	-0.12	-0.64	-0.69	-0.53	0.04	-0.09		0.02	-0.28	-0.86	-0.62	-0.09	-0.89	-0.52	-0.47	-0.01	-0.4	-0.08	-0.28	-0.47	-0.01	-0.12	-0.64	0.11
Retained Earnings	-0.8	-0.98	-0.91	-0.73	-0.62	-0.82	-0.97	-0.79	0.02		-0.89	-0.5	-0.65	-0.91	0.0	-0.84	-0.86	-0.9	-0.89	-0.56	-0.95	-0.82	-0.97	-0.89	-0.73	-0.94
Accounts Payable	0.94	0.88	0.95	0.89	0.79	0.95	0.86	0.85	-0.28	-0.89		0.68	0.87	0.92	0.13	0.95	0.96	0.89	0.97	0.62	0.93	0.94	0.9	0.94	0.89	0.8
Cash	0.87	0.48	0.53	0.89	0.91	0.84	0.47	0.47	-0.86	-0.5	0.68		0.86	0.47	0.77	0.84	0.8	0.43	0.76	0.4	0.71	0.78	0.5	0.55	0.89	0.42
Non Current Assets Total	0.96	0.67	0.72	0.97	0.88	0.93	0.62	0.64	-0.62	-0.65	0.87	0.86		0.73	0.37	0.91	0.89	0.64	0.88	0.39	0.82	0.95	0.72	0.68	0.97	0.53
Non Currrent Assets Other	0.83	0.91	0.92	0.79	0.6	0.85	0.84	0.79	-0.09	-0.91	0.92	0.47	0.73		-0.09	0.86	0.89	0.91	0.92	0.41	0.89	0.9	0.93	0.84	0.79	0.77
Other Assets	0.4	-0.08	0.06	0.45	0.53	0.39	-0.05	0.08	-0.89	0.0	0.13	0.77	0.37	-0.09		0.39	0.34	-0.13	0.27	0.09	0.19	0.26	-0.09	0.08	0.45	-0.06
Cash And Short Term Investments	0.99	0.82	0.89	0.97	0.86	1.0	0.79	0.79	-0.52	-0.84	0.95	0.84	0.91	0.86	0.39		1.0	0.79	0.99	0.5	0.94	0.97	0.84	0.85	0.97	0.72
Common Stock Total Equity	0.98	0.83	0.92	0.96	0.84	0.99	0.8	0.81	-0.47	-0.86	0.96	0.8	0.89	0.89	0.34	1.0		0.82	1.0	0.52	0.94	0.97	0.85	0.88	0.96	0.73
Common Stock Shares Outstanding	0.75	0.89	0.85	0.68	0.67	0.77	0.85	0.65	-0.01	-0.9	0.89	0.43	0.64	0.91	-0.13	0.79	0.82		0.84	0.73	0.85	0.8	0.88	0.92	0.68	0.81
Short Term Investments	0.97	0.87	0.94	0.94	0.8	0.99	0.83	0.84	-0.4	-0.89	0.97	0.76	0.88	0.92	0.27	0.99	1.0	0.84		0.5	0.95	0.97	0.89	0.88	0.94	0.76
Non Current Liabilities Total	0.47	0.54	0.49	0.38	0.66	0.49	0.61	0.32	-0.08	-0.56	0.62	0.4	0.39	0.41	0.09	0.5	0.52	0.73	0.5		0.54	0.42	0.51	0.79	0.38	0.64
Capital Surpluse	0.92	0.96	0.9	0.89	0.77	0.92	0.94	0.79	-0.28	-0.95	0.93	0.71	0.82	0.89	0.19	0.94	0.94	0.85	0.95	0.54		0.93	0.96	0.87	0.89	0.89
Other Current Assets	0.98	0.83	0.86	0.98	0.83	0.97	0.77	0.75	-0.47	-0.82	0.94	0.78	0.95	0.9	0.26	0.97	0.97	0.8	0.97	0.42	0.93		0.86	0.79	0.98	0.68
Other Stockholder Equity	0.81	1.0	0.9	0.76	0.62	0.82	0.97	0.79	-0.01	-0.97	0.9	0.5	0.72	0.93	-0.09	0.84	0.85	0.88	0.89	0.51	0.96	0.86		0.86	0.76	0.93
Total Liab	0.81	0.87	0.92	0.73	0.71	0.84	0.89	0.81	-0.12	-0.89	0.94	0.55	0.68	0.84	0.08	0.85	0.88	0.92	0.88	0.79	0.87	0.79	0.86		0.73	0.88
Net Invested Capital	0.99	0.73	0.79	1.0	0.88	0.98	0.68	0.71	-0.64	-0.73	0.89	0.89	0.97	0.79	0.45	0.97	0.96	0.68	0.94	0.38	0.89	0.98	0.76	0.73		0.59
Property Plant And Equipment Gross	0.67	0.95	0.84	0.59	0.53	0.69	0.99	0.76	0.11	-0.94	0.8	0.42	0.53	0.77	-0.06	0.72	0.73	0.81	0.76	0.64	0.89	0.68	0.93	0.88	0.59

Click cells to compare fundamentals

Nurix TherapeuticsInc Account Relationship Matchups

Nurix TherapeuticsInc fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	396.3M	476.8M	416.8M	364.5M	419.2M	319.7M
Other Current Liab	700K	14.5M	22.4M	25.0M	28.7M	30.2M
Total Current Liabilities	44.5M	66.3M	70.7M	87.0M	100.0M	58.2M
Total Stockholder Equity	290.3M	342.3M	303.7M	200.5M	230.6M	191.1M
Other Liab	37.4M	61.5M	59.0M	36.0M	41.4M	42.9M
Net Tangible Assets	(57.7M)	290.3M	342.3M	303.7M	349.3M	185.2M
Property Plant And Equipment Net	6.7M	25.3M	29.5M	48.0M	55.1M	57.9M
Current Deferred Revenue	32.8M	41.2M	37.6M	48.1M	55.3M	36.3M
Net Debt	(119.4M)	(67.5M)	(52.5M)	(24.0M)	(27.6M)	(29.0M)
Retained Earnings	(103.7M)	(220.9M)	(401.3M)	(545.2M)	(490.7M)	(466.1M)
Accounts Payable	3.4M	6.7M	5.1M	6.4M	7.4M	4.5M
Cash	119.4M	80.5M	64.5M	54.6M	62.8M	69.6M
Non Current Assets Total	97.9M	165.7M	98.3M	69.0M	79.4M	80.7M
Non Currrent Assets Other	347K	3.1M	4.9M	3.8M	4.4M	2.4M
Other Assets	317K	91.2M	3.1M	4.9M	5.7M	5.4M
Cash And Short Term Investments	281.1M	295.7M	309.1M	287.9M	331.1M	229.3M
Common Stock Total Equity	4K	39K	45K	47K	54.1K	30.4K
Common Stock Shares Outstanding	15.7M	42.9M	48.6M	54.3M	62.5M	39.7M
Short Term Investments	161.8M	215.2M	244.7M	233.3M	268.3M	159.7M
Liabilities And Stockholders Equity	396.3M	476.8M	416.8M	364.5M	419.2M	319.7M
Non Current Liabilities Total	61.5M	68.2M	42.4M	77.1M	88.7M	70.5M
Capital Surpluse	2.7M	393.8M	563.8M	709.2M	815.6M	856.4M
Other Current Assets	5.9M	9.2M	9.3M	6.8M	7.8M	6.3M
Other Stockholder Equity	(2.5M)	563.8M	709.2M	746.3M	858.2M	901.2M
Total Liab	106.1M	134.5M	113.1M	164.0M	188.7M	128.6M
Net Invested Capital	290.3M	342.3M	303.7M	200.5M	230.6M	191.1M
Long Term Investments	90.9M	137.2M	63.9M	7.4M	8.5M	8.1M
Property Plant And Equipment Gross	6.7M	25.3M	29.5M	74.2M	85.3M	89.6M
Total Current Assets	298.4M	311.1M	318.4M	295.5M	339.8M	239.0M
Accumulated Other Comprehensive Income	87K	(608K)	(4.3M)	(655K)	(589.5K)	(619.0K)
Capital Stock	39K	45K	47K	49K	56.4K	34.3K
Non Current Liabilities Other	1.7M	850K	68.2M	42.4M	48.8M	25.2M
Net Working Capital	253.9M	244.9M	247.8M	208.5M	239.8M	180.8M
Short Term Debt	7.6M	3.8M	5.5M	7.5M	8.6M	5.9M
Common Stock	39K	45K	47K	49K	56.4K	34.3K
Property Plant Equipment	3.9M	6.7M	25.3M	17.2M	19.7M	12.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Nurix TherapeuticsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nurix TherapeuticsInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nurix Therapeuticsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nurix Therapeuticsinc Stock:

How To Invest In Nurix

Details

Is Nurix Stock a good investment?

Details

What is Nurix TherapeuticsInc's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nurix TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Nurix Stock please use our How to Invest in Nurix TherapeuticsInc guide.

You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Nurix Stock analysis

When running Nurix TherapeuticsInc's price analysis, check to measure Nurix TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix TherapeuticsInc is operating at the current time. Most of Nurix TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Nurix TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix TherapeuticsInc's price. Additionally, you may evaluate how the addition of Nurix TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.

	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments

Is Nurix TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nurix TherapeuticsInc. If investors know Nurix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nurix TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.66)

Revenue Per Share

1.483

Quarterly Revenue Growth

0.307

Return On Assets

(0.29)

Return On Equity

(0.65)

The market value of Nurix TherapeuticsInc is measured differently than its book value, which is the value of Nurix that is recorded on the company's balance sheet. Investors also form their own opinion of Nurix TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Nurix TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nurix TherapeuticsInc's market value can be influenced by many factors that don't directly affect Nurix TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Nurix TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nurix TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nurix TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nurix Other Liab vs Capital Surpluse Analysis

Other Liab vs Capital Surpluse

Other Liab vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Other Liab

Capital Surpluse

Nurix TherapeuticsInc fundamental ratios Correlations

Nurix TherapeuticsInc Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Nurix TherapeuticsInc fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Nurix Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Stockholder Equity	+ 1.0	Other Current Liab
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Net Tangible Assets
Common Stock Total Equity	+ 1.0	Cash And Short Term Investments
Short Term Investments	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets

Retained Earnings	- 0.98	Other Current Liab
Other Stockholder Equity	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Property Plant And Equipment Net
Capital Surpluse	- 0.95	Retained Earnings
Property Plant And Equipment Gross	- 0.94	Retained Earnings
Non Currrent Assets Other	- 0.91	Retained Earnings